With a market capitalisation of ₹60,154 crores, the stock traded at ₹2,024.50 on July 23, down 0.56% on the day and languishing 25.57% below its 52-week high of ₹2,720.00. The results highlight the company's struggle to maintain profitability despite strong volume momentum in the fertiliser segment.
The quarter's performance reflects the challenging dynamics in the fertiliser industry, where input cost pressures and subdued realisations have compressed margins despite healthy volume growth. Net sales surged 15.94% year-on-year to ₹8,164.77 crores from ₹7,042.30 crores, driven by robust demand during the critical Kharif sowing season. However, operating profit margin (excluding other income) contracted 185 basis points to 9.26% from 11.11% in the year-ago quarter, indicating significant margin pressure.
| Quarter | Revenue (₹ Cr) | QoQ % | YoY % | Net Profit (₹ Cr) | QoQ % | YoY % | OPM % |
|---|---|---|---|---|---|---|---|
| Jun'26 | 8,164.77 | +36.00% | +15.94% | 380.82 | +172.15% | -24.59% | 9.26% |
| Mar'26 | 6,003.66 | -31.62% | +20.35% | 139.93 | -72.34% | -75.86% | 8.12% |
| Dec'25 | 8,779.45 | -9.06% | +26.59% | 505.88 | -37.18% | -1.15% | 9.11% |
| Sep'25 | 9,654.13 | +37.09% | — | 805.33 | +59.47% | — | 11.88% |
| Jun'25 | 7,042.30 | +41.17% | — | 505.01 | -12.88% | — | 11.11% |
| Mar'25 | 4,988.39 | -28.07% | — | 579.67 | +13.27% | — | 8.54% |
| Dec'24 | 6,935.19 | — | — | 511.77 | — | — | 10.41% |
Financial Performance: Growth Without Profitability
Coromandel International's Q1 FY27 results present a tale of two narratives—impressive revenue momentum countered by deteriorating profitability metrics. Net sales of ₹8,164.77 crores reflected strong demand across the company's fertiliser portfolio, particularly in complex fertilisers and specialty nutrients. The 36.00% sequential growth from Q4 FY26's ₹6,003.66 crores aligns with the seasonal uptick during the Kharif planting season, when farmer demand peaks.
However, the 24.59% year-on-year decline in consolidated net profit to ₹380.82 crores raises concerns about the sustainability of the current business model. Operating profit before depreciation, interest, and tax (excluding other income) stood at ₹755.65 crores, translating to a margin of just 9.26%—down sharply from 11.11% in Q1 FY26 and 11.88% in Q2 FY26. This 185 basis point year-on-year margin compression signals intensifying competitive pressures and input cost challenges.
The profit after tax margin deteriorated to 4.67% from 7.12% in Q1 FY26, a decline of 245 basis points. This compression was driven by multiple factors: higher employee costs (up 33.45% YoY to ₹300.83 crores), elevated interest expenses (up 31.00% YoY to ₹89.02 crores), and significantly higher depreciation charges (up 68.16% YoY to ₹202.76 crores). The sharp increase in depreciation reflects the company's substantial capital expenditure programme, with fixed assets surging to ₹6,070.21 crores in FY26 from ₹3,588.40 crores in FY25.
Other income declined 40.52% year-on-year to ₹49.81 crores from ₹83.74 crores, further pressuring bottom-line performance. The tax rate for the quarter stood at 25.72%, marginally lower than the 25.94% in Q1 FY26, providing minimal relief.
Margin Compression: A Deeper Look
The 185 basis point contraction in operating margin (excluding other income) from 11.11% to 9.26% year-on-year represents the steepest decline in recent quarters. This deterioration stems from subdued fertiliser realisations amid government-regulated pricing, elevated raw material costs including phosphoric acid and ammonia, and higher logistics expenses. The company's ability to pass through cost increases remains constrained in the heavily regulated fertiliser sector.
Capital Efficiency Under Pressure
Coromandel International's return on equity (ROE) has declined to 15.86% in the latest period from 19.79% on average, reflecting the challenges in generating adequate returns on shareholder capital. While the ROE remains respectable and above the cost of capital, the downward trajectory warrants attention. Higher ROE indicates better capital efficiency and profitability, making this decline a concern for long-term investors seeking superior returns.
The company's return on capital employed (ROCE) stood at 22.87% in the latest period, down from an average of 32.98%, indicating diminishing efficiency in deploying capital across the business. This deterioration coincides with the aggressive expansion programme, as evidenced by the 69.13% increase in fixed assets to ₹6,070.21 crores in FY26.
Balance sheet quality remains solid, with shareholder funds of ₹12,557.89 crores and minimal long-term debt of just ₹80.34 crores, resulting in a net debt-to-equity ratio of negative 0.07—meaning the company holds more cash than debt. Current assets of ₹15,847.08 crores comfortably exceed current liabilities of ₹10,465.44 crores, providing adequate liquidity. However, working capital management has tightened, with trade payables surging 46.39% to ₹8,827.13 crores in FY26.
⚠️ Profitability Warning
The sequential improvement in net profit (up 172.15% QoQ) masks the underlying weakness in year-on-year comparisons. The 24.59% YoY decline in consolidated profit, coupled with persistent margin compression, suggests structural challenges that extend beyond seasonal fluctuations. Investors should monitor whether management can reverse this trend in subsequent quarters.
Industry Context: Navigating Regulatory Headwinds
The fertiliser industry operates within a complex regulatory framework where the government controls prices and provides subsidies to farmers. This structure limits pricing flexibility for manufacturers like Coromandel International, making them vulnerable to input cost volatility. The company's performance must be viewed against the backdrop of subdued subsidy disbursements, fluctuating international raw material prices, and intense competition from both domestic and imported products.
The Kharif season (June to September) typically accounts for a significant portion of annual fertiliser sales, as farmers prepare for monsoon-dependent crops including rice, pulses, and oilseeds. Coromandel's 15.94% revenue growth in Q1 FY27 suggests healthy underlying demand, supported by normal monsoon predictions and government initiatives to boost agricultural productivity. However, the inability to translate this volume growth into proportionate profit growth highlights the margin pressures facing the sector.
The company's diversified product portfolio—spanning complex fertilisers, phosphatic fertilisers, specialty nutrients, crop protection chemicals, and retail operations—provides some insulation against segment-specific challenges. However, the core fertiliser business remains heavily regulated, constraining the company's ability to improve profitability through pricing actions.
| Company | P/E (TTM) | P/BV | ROE % | Dividend Yield | Debt/Equity |
|---|---|---|---|---|---|
| Coromandel Inter | 29.97 | 4.75 | 19.79% | 0.54% | -0.07 |
| F A C T | NA (Loss Making) | 37.97 | 48.76% | 0.02% | 1.17 |
| Deepak Fertilis. | 27.04 | 2.91 | 15.09% | 0.63% | 0.73 |
| Chambal Fert. | 8.86 | 1.66 | 18.86% | 2.32% | 0.00 |
| Paradeep Phosph. | 13.76 | 2.08 | 11.09% | 0.58% | 0.96 |
| EID Parry | 12.87 | 1.54 | 12.92% | — | 0.02 |
Coromandel International trades at a significant premium to most fertiliser peers, with a price-to-earnings ratio of 29.97x compared to Chambal Fertilisers' 8.86x and Paradeep Phosphates' 13.76x. The premium valuation of 4.75x price-to-book versus the sector average of approximately 2.0x reflects the market's historical confidence in Coromandel's execution capabilities and diversified business model. However, with ROE of 19.79%—only marginally ahead of Chambal's 18.86% but well below FACT's 48.76%—the valuation premium appears increasingly difficult to justify given the recent profit deterioration.
Valuation Analysis: Premium Pricing Meets Profit Pressure
At the current market price of ₹2,024.50, Coromandel International commands a market capitalisation of ₹60,154 crores, making it the largest company in the fertilisers sector. The stock trades at 29.97x trailing twelve-month earnings, a substantial premium to the industry average P/E of 23x. This 30% premium reflects the market's recognition of Coromandel's strong brand equity, extensive distribution network, and integrated operations spanning manufacturing to retail.
However, the valuation appears stretched when examined through multiple lenses. The price-to-book value of 4.75x significantly exceeds the sector norm, whilst the PEG ratio of 2.72 suggests the stock is expensive relative to its growth prospects. With earnings growth decelerating and margins under pressure, the premium valuation leaves limited room for disappointment.
The enterprise value-to-EBITDA multiple of 18.30x and EV-to-EBIT of 21.94x further confirm the premium valuation. The dividend yield of just 0.54% provides minimal income support, with the company maintaining a conservative dividend payout ratio of 21.38%. The stock's 52-week performance has been disappointing, declining 12.62% over the past year whilst the Sensex fell 7.66%, resulting in negative alpha of 4.96 percentage points.
The proprietary Mojo Score of 34 out of 100 places the stock firmly in "SELL" territory, reflecting concerns about valuation richness, deteriorating financial trends, and bearish technical momentum. The valuation grade has been classified as "VERY EXPENSIVE" since June 2024, indicating sustained overvaluation relative to fundamentals.
Shareholding Pattern: Promoter Reduction Raises Questions
The shareholding pattern reveals a gradual but consistent decline in promoter holding, which has decreased from 56.96% in March 2025 to 56.35% in March 2026—a reduction of 61 basis points over four quarters. The sequential decline of 51 basis points in Q4 FY26 alone represents the largest single-quarter reduction in recent periods. E.I.D. Parry (India) Limited, the primary promoter entity and part of the Murugappa Group, holds 55.58% of the company.
| Quarter | Promoter % | Change | FII % | Change | MF % | Change | Insurance % | Change |
|---|---|---|---|---|---|---|---|---|
| Mar'26 | 56.35% | -0.51% | 13.02% | -0.78% | 13.69% | +0.75% | 2.87% | +0.37% |
| Dec'25 | 56.86% | -0.02% | 13.80% | -0.71% | 12.94% | -0.11% | 2.50% | +0.54% |
| Sep'25 | 56.88% | -0.02% | 14.51% | +0.22% | 13.05% | -0.07% | 1.96% | -0.01% |
| Jun'25 | 56.90% | -0.06% | 14.29% | +3.68% | 13.12% | -1.86% | 1.97% | -1.29% |
| Mar'25 | 56.96% | — | 10.61% | — | 14.98% | — | 3.26% | — |
Foreign institutional investor (FII) holding has declined from 14.51% in September 2025 to 13.02% in March 2026, suggesting waning international investor confidence. The 78 basis point sequential decline in Q4 FY26 represents meaningful selling pressure from overseas funds. Conversely, mutual fund holdings increased from 12.94% to 13.69% in the latest quarter, indicating some domestic institutional support. Insurance company holdings also rose from 2.50% to 2.87%, suggesting select long-term investors are adding positions despite the challenging fundamentals.
The total institutional holding stands at 31.23%, comprising 630 FIIs and 36 mutual funds. The divergence between domestic and foreign institutional behaviour—with domestic funds accumulating whilst FIIs reduce exposure—reflects differing views on the company's medium-term prospects. The modest 0.01% promoter pledging indicates no immediate financial stress at the promoter level.
Stock Performance: Underperformance Across Timeframes
Coromandel International's stock has significantly underperformed the broader market across most relevant timeframes, with particularly stark underperformance over the past year. The stock has declined 12.62% over the last 12 months compared to the Sensex's 7.66% fall, generating negative alpha of 4.96 percentage points. Year-to-date performance shows a 10.95% decline versus the Sensex's 10.36% fall, marginally underperforming by 59 basis points.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +0.11% | -1.03% | +1.14% |
| 1 Month | +1.55% | +0.25% | +1.30% |
| 3 Months | -0.69% | -1.64% | +0.95% |
| 6 Months | -9.88% | -6.31% | -3.57% |
| YTD | -10.95% | -10.36% | -0.59% |
| 1 Year | -12.62% | -7.66% | -4.96% |
| 2 Years | +27.83% | -5.02% | +32.85% |
| 3 Years | +106.31% | +14.56% | +91.75% |
| 5 Years | +132.85% | +44.20% | +88.65% |
The medium-term picture remains challenging, with six-month returns of negative 9.88% underperforming the Sensex's 6.31% decline by 357 basis points. Short-term momentum has improved marginally, with one-week returns of positive 0.11% outperforming the Sensex's 1.03% decline, and one-month returns of 1.55% beating the index's 0.25% gain by 130 basis points.
Long-term investors have fared significantly better, with three-year returns of 106.31% vastly outperforming the Sensex's 14.56% gain, generating positive alpha of 91.75 percentage points. Five-year returns of 132.85% versus the Sensex's 44.20% demonstrate the stock's historical wealth-creation potential. However, this long-term outperformance appears to be eroding, with recent underperformance suggesting a potential inflection point in the stock's trajectory.
The stock currently trades 25.57% below its 52-week high of ₹2,720.00 achieved in early 2026, but remains 18.43% above the 52-week low of ₹1,709.50. Technical indicators paint a bearish picture, with the stock classified as "MILDLY BEARISH" and trading below all major moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. The risk-adjusted return of negative 0.39 with volatility of 32.59% places the stock in the "MEDIUM RISK MEDIUM RETURN" category, though recent returns have been decidedly negative.
Investment Thesis: Quality Business Facing Cyclical Headwinds
Coromandel International's investment case rests on several pillars: market leadership in the fertiliser sector, diversified product portfolio spanning nutrients and crop protection, extensive pan-India distribution network with strong rural reach, and backing from the reputable Murugappa Group. The company's integrated operations from raw material sourcing to retail distribution provide competitive advantages in a fragmented industry.
However, the investment thesis faces significant near-term challenges. The deteriorating financial trend, with quarterly profit declining 24.59% year-on-year despite revenue growth, raises questions about operational execution and cost management. Margin compression of 185 basis points in operating profit margin (excluding other income) indicates structural pressures that may persist given the regulated nature of the fertiliser industry.
The valuation premium of 29.97x earnings—30% above the sector average—appears increasingly difficult to justify given the profit decline and margin pressure. With the stock classified as "VERY EXPENSIVE" and trading at 4.75x book value versus sector norms of approximately 2.0x, the risk-reward equation tilts unfavourably. The declining ROE from 19.79% average to 15.86% latest further undermines the premium valuation argument, as capital efficiency deteriorates.
Key Strengths
- Market leadership in Indian fertiliser sector with strong brand equity
- Diversified product portfolio across nutrients, crop protection, and retail
- Extensive distribution network providing deep rural market penetration
- Strong balance sheet with negative net debt and minimal leverage
- Part of reputable Murugappa Group with 60+ year operating history
- High institutional holdings of 31.23% indicating quality investor base
- Integrated operations from manufacturing to retail providing cost advantages
Key Concerns
- Net profit declined 24.59% YoY despite 15.94% revenue growth
- Operating margin compressed 185 bps to 9.26% from 11.11% YoY
- ROE deteriorated to 15.86% from 19.79% average, indicating lower capital efficiency
- Premium valuation at 29.97x P/E (30% above sector) difficult to justify
- Stock underperformed market by 4.96% over past year with negative alpha
- Promoter holding declined 61 bps over four quarters to 56.35%
- Heavily regulated industry limits pricing flexibility and margin expansion
Outlook: What to Watch in Coming Quarters
The trajectory for Coromandel International over the next two to three quarters will depend critically on the company's ability to arrest margin compression and restore profitability growth. Management's commentary on raw material cost trends, particularly phosphoric acid and ammonia prices, will be crucial. The company's success in passing through cost increases within the regulated pricing framework will determine whether margins can stabilise or continue deteriorating.
Positive Catalysts
- Stabilisation or decline in key raw material costs (phosphoric acid, ammonia)
- Timely government subsidy disbursements improving working capital cycle
- Market share gains in specialty nutrients and crop protection segments
- Normal monsoon supporting healthy fertiliser demand in Kharif season
- Margin recovery driven by operational efficiencies and product mix improvement
Red Flags
- Further margin compression below 9% operating margin threshold
- Continued decline in quarterly profit on year-on-year basis
- Additional promoter stake reduction or accelerated FII selling
- Delayed subsidy payments from government straining working capital
- Raw material cost escalation without corresponding pricing adjustments
Investors should monitor quarterly margin trends closely, with particular focus on whether operating margins can recover toward the 10-11% range achieved historically. The company's ability to grow profits in line with or ahead of revenue growth will be the key determinant of whether the current valuation premium can be sustained. Working capital management and cash generation will also merit attention, given the significant increase in trade payables and the capital-intensive nature of recent expansion.
The shareholding pattern deserves continued scrutiny, particularly any further reduction in promoter holding or accelerated FII selling. A reversal of these trends would provide confidence, whilst continued selling pressure would signal deeper concerns about the medium-term outlook. Technical indicators suggest the stock may test support levels around ₹1,900-1,950 if selling pressure intensifies, whilst resistance appears firm at the 200-day moving average of ₹2,127.44.
The Verdict: Premium Valuation Meets Profit Pressure
Score: 34/100
For Fresh Investors: Avoid initiating positions at current levels. The combination of deteriorating profitability (24.59% YoY profit decline), compressed margins (9.26% vs 11.11% YoY), and premium valuation (29.97x P/E, 30% above sector) creates an unfavourable risk-reward equation. Wait for meaningful margin recovery and profit stabilisation before considering entry.
For Existing Holders: Consider reducing exposure or booking profits, particularly if holding from lower levels. The stock's 25.57% decline from 52-week highs reflects deteriorating fundamentals that may persist for several quarters. Long-term investors with high conviction in the Murugappa Group's execution capabilities may hold with a 3-5 year horizon, but should prepare for continued near-term volatility and potential further downside toward ₹1,800-1,900 levels.
Fair Value Estimate: ₹1,750 (13.56% downside from current levels), based on 25x P/E applied to normalised earnings of ₹70 per share, assuming margin recovery to 10% operating margin over the next 12-18 months.
Coromandel International remains a quality franchise with strong market positioning, but the current valuation offers inadequate margin of safety given near-term profit pressure and margin compression. The stock may present better entry opportunities at ₹1,700-1,800 levels, representing 15-20% downside, where the valuation would better reflect the challenging operating environment and provide adequate compensation for execution risks.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. All investments carry risk, including potential loss of principal.
